GBA1 and Parkinson disease: Standard clinical practice should entail the routine dissemination of information regarding the lifetime risk of PD to both heterozygous and biallelic GBA1 carriers directly from clinicians and trained genomic counselors (1) before GBA1 testing to ensure informed consent, and (2) at diagnosis after the establishment of patient preference for genetic result disclosure.